Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

PHASE3CompletedINTERVENTIONAL
Enrollment

836

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

July 31, 2010

Study Completion Date

August 31, 2010

Conditions
Major Depressive Disorder
Interventions
DRUG

Vortioxetine

Encapsulated vortioxetine immediate-release tablets

Trial Locations (92)

Unknown

Beverly Hills

Irvine

Santa Ana

Torrance

Upland

Bradenton

Coral Springs

Fort Walton Beach

Gainesville

Jacksonville

Maitland

Orlando

South Miami

West Palm Beach

Atlanta

Smyrna

Chicago

Libertyville

Oak Brook

Prairie Village

Owensboro

Baltimore

Pittsfield

Worcester

Flowood

New York

Olean

Beachwood

Toledo

Oklahoma City

Allenport

Lancaster

Memphis

Austin

San Antonio

Salt Lake City

Seattle

Milwaukee

Elizabeth Vale

Richmond

Southport

Osijek

Zagreb

Bully-les-Mines

Marseille

Strasbourg

Berlin

Bochum

Chemnitz

Hüttenberg

Leipzig

München

Nuremberg

Wiesbaden

Liepāja

Riga

Sigulda

Šiauliai

Vilnius

Kuala Lumpur

SchHoogfliet

Wildervank

Zwijndrecht

Bialystok

Leszno

Pruszków

Skórzewo

Torun

Tuszyn

Moscow

Nizhny Novgorod

Novosibirsk

Omsk

Saint Petersburg

Stavropol

Tomsk

Belgrade

Bryanston

Durban

Lyttelton

Noordheuwel

Pretoria

Buchon

Gyeonggi-do

Incheon

Seoul

Kaohsiung City

Dnipro

Kiev

Luhansk

Simferopol

Glasgow

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

H. Lundbeck A/S

INDUSTRY

lead

Takeda

INDUSTRY

NCT00707980 - Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder | Biotech Hunter | Biotech Hunter